GRANITE

P2/3 | N=700 | NCT05141721 | Sponsor: Gritstone bio, Inc. | "Gritstone bio...announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE...in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC)....Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a high-risk group, where clinical data are more mature ([95% CI, 0.15-1.38]; 44% censored); >90% of high-risk patients have liver metastases....GRANITE was generally well-tolerated with manageable adverse events; no patients have discontinued GRANITE due to adverse events....Mature PFS data expected in the third quarter of 2024; overall survival data expected in 1H 2025."

P2, N=1, Terminated, Gritstone bio, Inc. | N=142 --> 1 | Trial completion date: Sep 2026 --> Sep 2022 | Recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Sep 2022; terminated due to reprioritization

P2, N=142, Recruiting, Gritstone bio, Inc.

P2/3; N=665; Not yet recruiting; Sponsor: Gritstone Oncology, Inc.